Novartis: Choroidal Neovascularization trials

The registry lists 29 Choroidal Neovascularization studies with Novartis as lead sponsor. 0 are open to participants now and 22 have results posted.

Phase 1 2Phase 2 4Phase 3 15Phase 4 8No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)CompletedNCT05269966Phase 4Results posted
• Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.CompletedNCT04774926Phase 4Results posted
• Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular DegenerationCompletedNCT04679935Phase 4Results posted
• An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) StudyCompletedNCT04597632Phase 3Results posted
• Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular DegenerationCompletedNCT04264819Phase 3Results posted
• A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular DegenerationCompletedNCT04239027Phase 3Results posted
• Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)CompletedNCT04005352Phase 3Results posted
• A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.CompletedNCT02034006Phase 3Results posted
• Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)CompletedNCT01972789Phase 4Results posted
• Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMDCompletedNCT01948830Phase 3Results posted
• Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic MyopiaCompletedNCT01922102Phase 3Results posted
• An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.CompletedNCT01908816Phase 3Results posted
• Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.CompletedNCT01840410Phase 3Results posted
• Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVOCompletedNCT01580020Phase 4Results posted
• Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic MyopiaCompletedNCT01217944Phase 3Results posted
• Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD)CompletedNCT01148511Phase 4Results posted
• The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular DegenerationTerminatedNCT00857259Phase 2Results posted
• Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal NeovascularizationCompletedNCT00436553Phase 3Results posted
• Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)TerminatedNCT00433017Phase 2/3Results posted
• SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular DegenerationCompletedNCT00331864Phase 3Results posted
• Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular DegenerationCompletedNCT00284089Phase 1/2Results posted
• A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal PegaptanibCompletedNCT00242580Phase 3Results posted
• Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved IndicationsCompletedNCT04847895
• A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)CompletedNCT01542866Not applicable
• Intravitreal LFG316 in Patients With Advanced Age-related Macular DegenerationCompletedNCT01255462Phase 1
• Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized RegimenCompletedNCT01037348Phase 2
• Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular DegenerationCompletedNCT00504959Phase 4
• EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)CompletedNCT00470678Phase 3
• Photodynamic Therapy in Occult-Only Lesions (POOL)CompletedNCT00135837Phase 4